# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹81 Cr** Q2 FY'26 · **₹152 Cr** H1 FY'26 * **PAT:** **₹6.5 Cr** Q2 FY'26 · **₹10.1 Cr** H1 FY'26 * **Operating Cash Flow:** **₹44 Cr** H1 FY'26 (vs. ₹22 Cr prior year) · **EBITDA to OCF conversion: 85%** (vs. 50%) ## B. Revenue Growth * **Volume-Driven Expansion:** Revenue growth is purely volume-led, with no price changes, underscoring strong market share gains in the life science segment. * **Outperformance vs. Sector:** Top-line momentum reflects Tarsons’ competitive edge from product quality and brand trust, outpacing broader industry trends. ## C. EBITDA Margins * **Significant Margin Leverage:** EBITDA margins expanded over 300 bps YoY, driven by operating scale and disciplined cost management despite semi-variable cost structure. * **Pricing Discipline Maintained:** No broad price reductions; selective volume-based discounts used strategically to support growth without eroding margins. * **Expense Pressures:** Other expenses rose sharply YoY, partly due to a prior-period write-off of **₹6 Cr**, though detailed cost breakdown is not publicly disclosed. ## D. Profit After Tax * **PAT Under Pressure from Non-Operating Costs:** Decline in profitability driven by **accelerated depreciation** and **high borrowing costs** linked to ongoing capacity expansion. * **Depreciation Impact:** Q2 PAT decline attributed to **₹20 Cr in higher depreciation** from partial capitalization of the Panchla facility. ## E. Cash Flow Conversion * **Strong Cash Flow Generation:** Operating cash flow more than doubled, with EBITDA-to-OCF conversion improving to **85%**, signaling enhanced working capital efficiency. * **Sustainable Business Model:** Rising cash PAT highlights underlying earnings quality despite near-term earnings volatility from expansion-related costs. --- # 2. Capacity & Production ## A. Key Figures * **Capacity Utilization:** ~**80%** on existing plant * **Capex Outflow (H1):** **₹71 Cr** * **CWIP:** **₹251 Cr** (majority Panchla & Amta) * **Net Block (est. FY26):** **₹760 Cr** * **Peak Revenue Potential (New Facilities):** **₹350–400 Cr** * **Total Capex (Est. Range):** **₹550–650 Cr** (Panchla: ₹300 Cr, Amta: ₹150 Cr, Existing Plants: ₹100 Cr) ## B. Panchla Ramp-Up * **Phased Commissioning Underway:** Panchla facility partially operational with initial sales in PETG and roller bottles; full ramp-up targeted by Q4 FY26. * **Growth-Focused Expansion:** Facility to scale capacity for existing bioprocess products and launch new offerings, with no legacy site closures. * **Lean Start, Gradual Scaling:** Minimal current staffing with plans to increase in line with volume growth. ## C. Amta Commissioning * **Strategic De-Risking:** ₹150 Cr Amta investment primarily secures in-house sterilization, reducing reliance on a single external vendor. * **Multi-Function Facility:** Will house fulfilment, sterilization, and manufacturing, with production expected to commence in the coming months. ## D. Utilization Rates * **Demand Outstrips Capacity:** Strong global order inflow constrained by current 80% utilization and ongoing machine commissioning. ## E. Capex Completion * **Near-Term Asset Conversion:** CWIP of ₹251 Cr and capital advances of ₹64 Cr to be transferred to fixed assets in Q3 and Q4 FY26. * **Long-Term Growth Enabler:** Capex surge (gross block up from ₹160 Cr to ₹730 Cr) positions company for multi-year revenue expansion. --- # 3. Product & Segment Performance ## A. Key Figures * **Consolidated Revenue:** **₹102 Cr** Q2FY26 (+3%) · **₹22 Cr** contribution from Nerbe * H1 FY26 Nerbe Revenue: **₹193.7 Cr** * **Cell Culture Revenue Outlook:** **₹100–125 Cr** from existing products (of ₹350–400 Cr total) ## B. Bioprocess Launches * **Strategic Expansion:** Robust long-term growth outlook in plastic labware, supported by rising global and domestic demand in life sciences and research. * **Product Rollout Momentum:** New bioprocess products (PET, PETG, roller bottles) launched, with cell culture products expected within 2–3 months, signaling accelerated innovation cycle. * **Gradual Commercialization:** Sales ramp-up expected in Q3–Q4 due to customer validation timelines, though high import lead times create substitution tailwinds. ## C. ODM Demand * **Strong ODM Inquiries:** High interest in ODM contracts domestically and internationally, reflecting confidence in Tarsons’ design and manufacturing capabilities. * **Customer Monetization:** New product launches are deepening relationships with existing customers and expanding wallet share across segments. * **Margin Parity Internationally:** ODM and branded products yield similar gross margins overseas, despite lower overall international margins due to competitive intensity. ## D. Nerbe Integration * **Strategic, Not Financial:** Nerbe acquisition aimed at leveraging brand strength in Germany and product overlap to expand regional footprint, not immediate financial accretion. * **Challenged but Resilient:** Nerbe delivered flat growth amid German economic headwinds and degrowth in peer firms, though supply constraints persist due to organic capex prioritization. * **Supply Restart Imminent:** Tarsons plans to begin supplying Nerbe post-capex ramp-up, with a new product launch targeted to reinvigorate Nerbe brand sales. ## E. Cell Culture Edge * **First-Mover Advantage:** Tarsons is the only Indian player with a domestic cell culture facility, positioning it to capture early-mover benefits over the next 1–2 years. * **Near-Term Revenue Visibility:** Majority of existing cell culture products are pre-validated and expected to sell rapidly, supporting strong initial uptake. --- # 4. Export & Geography Mix ## A. Key Figures * **Domestic Revenue:** **₹215 Cr** (latest FY) * **Indian Plastic Labware Market Size:** **₹1,200 Cr** * **Historical Market Shift:** Plastic share rose from **25% to 50%** over two decades ## B. U.S. Order Book * **Export Volatility Explained:** Recent decline in export revenue attributed to **logistical bottlenecks**, specifically delayed bills of lading, not weakening demand. * **Global Traction Building:** Tarson is an emerging exporter with **growing interest from major OEMs and branded customers**, supported by direct factory supply requirements and facility audits. ## C. European Inquiries * **Pipeline Strength:** Robust international inquiry flow, particularly in Europe, expected to convert into orders as product portfolio scales. * **Market Entry Dynamics:** New geography onboarding is agile—**sample testing takes 1–2 months**—though customer conversion timelines vary with trust-building. ## D. Domestic Penetration * **Penetration Over Expansion:** Focus on increasing wallet share within existing domestic accounts amid **intense competition and pricing pressure** from new entrants. * **Regional Imbalance:** Sales concentration in **South and West India** driven by pharma/biopharma cluster density; North and East show structural demand limitations. * **Market Growth Reassessment:** Full-year domestic market growth remains uncertain; prior Frost & Sullivan projections for FY25 appear unattainable due to **post-COVID market sluggishness**. ## E. Regional Demand * **Export Resilience:** Flattish export trends over three quarters reflect **shipment timing issues**, not erosion in U.S. customer demand or order intake. * **Currency Impact:** Reported growth in Nerbe is solely due to **rupee depreciation**, with **no real constant-currency volume growth**. * **Demand Drivers Clarified:** Indian plastic labware growth stems from **overall market expansion**, not substitution from glass, which has already reached parity. --- # 5. Input Cost & Regulatory Risks ## A. Key Figures * **Depreciation Peak:** **₹85–90 Cr** FY'26 · **₹100–105 Cr** FY'27 * Sterilization Costs: ~1.5% of top line (FY'24 and prior) ## B. U.S. Tariff Impact * **No Customer or Order Loss:** U.S. tariffs at 50% have not disrupted demand, with **ongoing order inflows under current conditions** due to strong customer relationships. * **Pricing on Hold:** The company is **not passing through tariff costs** and awaits resolution of the U.S. trade deal before implementing price adjustments. * **Full Compliance Emphasized:** Exports strictly follow legal channels with proper **certificate of origin documentation**, rejecting any bypass tactics. * **Competitive Pressure Rising:** MNCs now subcontract locally, eroding Tarsons’ prior **pricing and brand advantage** through improved cost competitiveness. ## C. Depreciation Peak * **Depreciation Ramp-Up:** Significant increase expected from Q3 FY'26, with full capitalization by Q4 FY'26, driving stepped-up charges into FY'27. ## D. Freight Challenges * **External Headwinds Weighing on Growth:** Performance constrained by uncontrollable factors including **global economic conditions, freight volatility, BL implementation, and U.S. tariffs**. ## E. Compliance Costs * **In-House Sterilization Benefits Delayed:** Cost savings from internal radiation and sterilization will emerge gradually, driven by **operating leverage** as Panchla and Amta scale sterile production. --- # 6. Guidance & Outlook ## A. Key Figures * **Revenue Ramp-Up:** **INR 100–125 Cr** capacity expansion potential (3–5 years) * Capex Investment: INR 550–650 Cr total outlay, completion by Q4 FY'26 * Asset Turnover: Expected 0.7 to 0.8x on gross block post-capex ## B. Revenue Ramp Timeline * **Long-Term Scaling Confidence:** Bullish revenue outlook underpinned by expanded portfolio, brand strength, and capacity, with full utilization expected over **3 to 5 years** for new products. * **Phased Capacity Absorption:** Existing product lines to reach full run-rate in **2–3 years**, while technically complex new products face longer gestation due to high entry barriers. * **Validation Momentum:** Positive early feedback on new product launches reinforces confidence in long-term ramp trajectory and **strong brand recall** in India and emerging markets. ## C. Margin Recovery * **Profitability Rebound in Sight:** Revenue and margin recovery expected in FY'27–FY'28, driven by higher utilization, favorable mix, and automation gains. * **Panchla Facility Catalyst:** Full commissioning of Panchla plant to restore **PAT margins to normalized levels**, marking a key inflection point. * **Pricing Pressure Persists:** Domestic market price hikes constrained by competition over next **2–3 years**, accelerating strategic pivot to exports. ## D. Export Growth View * **Export Momentum Building:** Healthy and growing order book reflects strong demand, though current delivery lags due to **capacity bottlenecks** and machine commissioning delays. * **Growth Expected by Year-End:** Fulfillment challenges anticipated to resolve, enabling export growth realization within the current fiscal. * **No Formal Guidance, But Optimism Intact:** Management maintains export upside view despite volatile global conditions and **unpredictable tariff environment**. ## E. Capex Outlook * **Capex Final Phase:** Major investments completed by Q4 FY'26, with residual payments extending up to **12 months** post-completion.